A FIRST-IN-HUMAN TRIAL OF HSTC810 (ANTI-BTN1A1 AB), A NOVEL IMMUNE CHECKPOINT WITH A MUTUALLY EXCLUSIVE EXPRESSION WITH PD-1/PD-L1, IN PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS

被引：1

作者：

Lee, Soohyeon ^{[1
]}

Shin, Sangjoon ^{[2
]}

Howie, Lynn ^{[3
]}

Jung, Hyunjin ^{[4
]}

Yoo, Steven ^{[3
,4
]}

Hong, David ^{[5
]}

机构：

[1] Korea Univ, Anam Hosp, Seoul, South Korea

[2] Yonsei Canc Ctr, Seoul, South Korea

[3] STCube Pharmaceut Inc, Gaithersburg, MD USA

[4] STCube Inc, Seoul, South Korea

[5] MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0740

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

740

引用

页码：A773 / A773

页数：1

共 50 条

[41] Immune Checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) Expression in Plasma Cell Myeloma
Lee, Min Young
Park, Chan-jeoung
Cho, Young-Uk
You, Eunkyoung
Jang, Seongsoo
Lee, Jung-Hee
Hong, Jung Yong
Yoon, Dok Hyun
Suh, Cheolwon
BLOOD, 2017, 130
[42] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
Rui, Xin
Gu, Ting-Ting
Pan, Hua-Feng
Zhang, Hui-Zhi
INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385
[43] Investigation of the PD-1 and PD-L1 Immune Checkpoint Molecules Throughout Healthy Human Pregnancy and in Nonpregnant Women
Meggyes, Matyas
Nagy, David U.
Szereday, Laszlo
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (08) : 1 - 16
[44] Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis
Solorzano-Ibarra, F.
Alejandre-Gonzalez, A. G.
Ortiz-Lazareno, P. C.
Bastidas-Ramirez, B. E.
Zepeda-Moreno, A.
Tellez-Banuelos, M. C.
Banu, N.
Carrillo-Garibaldi, O. J.
Chavira-Alvarado, A.
Bueno-Topete, M. R.
del Toro-Arreola, S.
Haramati, J.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2021, 204 (01) : 78 - 95
[45] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
Himuro, Hidetomo
Nakahara, Yoshiro
Igarashi, Yuka
Kouro, Taku
Higashijima, Naoko
Matsuo, Norikazu
Murakami, Shuji
Wei, Feifei
Horaguchi, Shun
Tsuji, Kayoko
Mano, Yasunobu
Saito, Haruhiro
Azuma, Koichi
Sasada, Tetsuro
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
[46] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
Hidetomo Himuro
Yoshiro Nakahara
Yuka Igarashi
Taku Kouro
Naoko Higashijima
Norikazu Matsuo
Shuji Murakami
Feifei Wei
Shun Horaguchi
Kayoko Tsuji
Yasunobu Mano
Haruhiro Saito
Koichi Azuma
Tetsuro Sasada
Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
[47] Plasma soluble PD-1/PD-L1 for prediction of prognosis in NSCLC patients treated with immune checkpoint inhibitors
Himuro, Hidetomo
Nakahara, Yoshiro
Igarashi, Yuka
Kouro, Taku
Murakami, Shuji
Wei, Feifei
Horaguchi, Shun
Tsuji, Kayoko
Mano, Yasunobu
Saito, Haruhiro
Azuma, Koichi
Sasada, Tetsuro
CANCER SCIENCE, 2024, 115 : 1381 - 1381
[48] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
Nakahara, Y.
Himuro, H.
Igarashi, Y.
Kouro, T.
Higashijima, N.
Matsuo, N.
Murakami, S.
Wei, F.
Horaguchi, S.
Tsuji, K.
Mano, Y.
Saito, H.
Azuma, K.
Naoki, K.
Sasada, T.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
[49] Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors
Wang, Miao
Zhen, Hongchao
Jiang, Xiaoyue
Lu, Yuting
Wei, Yuhan
Jin, Jiangtao
Li, Qin
IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1584 - 1595
[50] Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
Yk, Wang
Gong, Jifang
Sun, Yuping
Zhang, Jian
Ni, Shuqin
Hou, Jie
Chen, Xiaohua
Wang, Yusheng
Yu, Qin
Qu, Xiangdong
Du, Yejie
Wei, Li
Yu, Tao
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 382 - 382

← 1 2 3 4 5 →